Pds Biotechnology CORP 8-K filings

PDS Biotechnology Corporation announced a virtual Key Opinion Leader event on October 15, 2026, to discuss clinical outcomes of PDS0301 for advanced liver-associated cancers, focusing on metastatic colorectal cancer.

PDS Biotechnology Corporation announced the publication of positive Phase 2 trial results for its immunotherapy PDS0101 in combination with pembrolizumab for HPV16-positive head and neck cancer in JAMA Oncology.

PDS Biotechnology Corporation released an updated corporate presentation detailing progress on its PDS0301 and PDS0101 drug candidates, including promising clinical trial results and near-term catalysts.

PDS Biotechnology Corporation announced the initial closing of an $11.3 million PIPE financing and the appointment of Dr. Patrick Soon-Shiong to its Board of Directors, signaling strategic investment and leadership enhancement.

PDS Biotechnology Corporation announced a private placement financing of up to $22.55 million, led by Nant Capital, with Nant founder Dr. Patrick Soon-Shiong joining the board.

PDS Biotechnology Corporation has entered into a First Amendment to Promissory Note with YA II PN, Ltd., modifying terms related to ATM proceeds, Nasdaq listing deficiency cure periods, and non-ATM equity financings.

PDS Biotechnology Corporation is reducing its workforce by approximately 36% and has terminated its Chief Operating Officer as part of a strategic realignment.

PDS Biotechnology Corporation announced the resignation of its Chief Financial Officer, Lars Boesgaard, effective September 12, 2026, with interim appointments made for the Principal Financial and Accounting Officer roles.

PDS Biotechnology Corporation stockholders approved an amendment to increase authorized common stock from 150 million to 300 million shares at the 2026 annual meeting.

PDS Biotechnology Corporation announced a strategic refocus on its PDS0301 program, discontinuing the VERSATILE-003 Phase 3 trial for PDS0101 and reporting a net loss of $9.8 million for Q2 2026.

PDS Biotechnology Corporation announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer and will seek partnerships for PDS0101, discontinuing its Phase 3 trial.

PDS Biotechnology Corporation received a deficiency letter from Nasdaq for failing to meet the minimum $1.00 bid price requirement for its common stock.

PDS Biotechnology Corporation closed a $6 million promissory note and established a $50 million at-the-market offering program with YA II PN, LTD. and its affiliate Yorkville Securities, LLC.

PDS Biotechnology Corporation announced its 2026 Annual Meeting of Stockholders will be held on August 10, 2026, with a June 25, 2026 deadline for stockholder proposals.

PDS Biotechnology Corporation announced it has regained compliance with Nasdaq's minimum bid price requirement, closing a deficiency matter.

PDS Biotech reports Q1 2026 financial results, highlighting clinical advancements in cancer immunotherapies and a reduced net loss.

PDS Biotechnology has entered into a $6 million securities purchase agreement and initiated an at-the-market offering program while retiring existing senior secured debt.

PDS Biotechnology released an updated corporate presentation detailing progress on its Versamune and PDS01ADC immunotherapy platforms.

PDS Biotechnology Corporation reports promising interim Phase 2 clinical trial data for its PDS01ADC immunocytokine in metastatic colorectal cancer patients.

PDS Biotech reported a narrower 2025 net loss, amended its PDS0101 Phase 3 to use PFS for an accelerated approval path, highlighted encouraging PDS01ADC Phase 2 data, and ended the year with $26.7M in cash.

PDS Biotechnology Corporation received a deficiency letter from Nasdaq for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

PDS Biotechnology updates corporate presentation highlighting PDS0101's compelling clinical results and accelerated approval pathway for HPV16-positive head and neck cancers.

PDS Biotech amends its Phase 3 VERSATILE-003 trial protocol to include progression-free survival as an interim primary endpoint for potential accelerated FDA approval of PDS0101.

PDS Biotechnology announced positive preliminary Phase 2 results for its IL-12 immunocytokine, PDS01ADC, in metastatic castration-resistant prostate cancer.

PDS Biotechnology Corporation announced a Notice of Allowance for a new U.S. patent covering its lead asset, PDS0101, extending market protections for over 20 years.

PDS Biotech submitted a protocol amendment to the FDA for its Phase 3 VERSATILE-003 trial, aiming for accelerated approval of PDS0101 by changing the primary endpoint to Progression Free Survival.

PDS Biotechnology Corporation announced the Japan Patent Office issued a new patent for PDS0101, strengthening its global intellectual property portfolio and extending protection into the 2040s.

PDS Biotechnology announced a Type C meeting with the FDA to discuss an accelerated approval pathway for its lead immunotherapy PDS0101 for HPV16-positive head and neck cancer, based on positive VERSATILE-002 trial results.

PDS Biotechnology reported Q3 2025 financial results and announced plans to seek an accelerated approval pathway for its lead immunotherapy, PDS0101, based on positive Phase 2 trial data.

PDS Biotechnology Corporation announced a registered direct offering of common stock and warrants, aiming to raise up to $11.1 million to advance its immunotherapy clinical trials.